The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Assessing BGB-11417, a novel BCL2 inhibitor, in NHL
Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, The Peter MacCallum Cancer Centre, Melbourne, Australia, discusses preliminary data from the Phase I BGB-11417-101 trial (NCT04277637) of BGB-11417, a novel BCL2 inhibitor, with zanubrutinib in patients with non-Hodgkin lymphoma (NHL). Patients in the dose-escalation trial reported encouraging efficacies across different indications including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), and the drug additionally demonstrated an acceptable safety profile. BGB-11417 continues to be a promising candidate drug superior to venetoclax. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
